tbuckley/cabot-search huggingface dataset:
Soundings: Death, where is thy sting?
Authors: Liam Farrell
Journal: BMJ (2003)

I'm an old fashioned general practitioner; Dr Finlay and I would have got on famously, gone out drinking together, maybe clubbing in Ibiza, etc. I still enjoy home visits, and value the precious insights gained from enjoying cups of tea and big slices of home made apple pie in the kitchen with Granny Arbuckle, before drinking quarts of cider and sneaking off for a quick shag with her buxom niece Sally amid the fields of barley (OK, I made the last bit up; it seems such a logical progression).

But house calls aren't always fun, especially at a spooky time like Halloween.

The cottage was deep in the woods. As usual, on calls where the welcome is uncertain, I parked facing away from the house and on a down slope, and left the engine running, all to facilitate a quick getaway.

The countryside, so familiar during the day, seemed now veiled and threatening, and the menacing eyes of sheep loomed up on every side. You city folk think sheep are cuddly and innocent, but get between a pack of sheep and their prey, and you're in for a stomping.

The farmyard was guarded by a three-headed hound carrying a knife and fork, which struck me as curious yet apt. It snarled at me affectionately, but I placated it by stuffing my fingers up its nostrils until it suffocated; animals respond to kindness, don't you know.

I knocked, there being a huge knocker on the door, and entered.

The skeletal figure of Death sat in front of a waning fire. He pointed a bony finger at me.

“I have a task for you, doctor,” he said in a voice both sepulchral and nasal. “I have an awful cough, and I thought maybe... an antibiotic.”

He hawked noisily and, I thought, a tad theatrically, and spat generously into the grate, only lightly spraying me on the way. There was a whoosh and sizzle, and the dying embers wrought their ghost upon the floor a month earlier than usual.

My clinical instincts are always alert and I noticed from the specks on my silk cravat that his sputum was non-purulent. I explained firmly that he had a viral illness, and he should rest and take plenty of fluids.

He sagged in disappointment, then perked up again, “My back's giving me gyp,” he said, “what about an x ray?”
NCO-13NEUROCOGNITIVE CHANGES ASSOCIATED WITH FRONTAL LOBECTOMY FOR RIGHT AND LEFT FRONTAL LOBE GLIOMA
Authors: Petya Demireva, Kyle Noll, Jonathan Sellin, Sujit Prabhu, Jeffrey Wefel
Journal: Neuro-Oncology (2015)

BACKGROUND: Some patients with frontal lobe glioma receive near frontal lobectomy for tumor resection or debulking. However, little is known regarding the impact of frontal lobectomy for glioma on neurocognitive functioning (NCF). METHODS: Patients with glioma in the left (n = 11; 78% anaplastic) or right frontal lobe (n = 9; 73% anaplastic) underwent frontal lobectomy. The posterior resection boundary included the frontal pole of the lateral ventricle and posterior floor of the anterior cranial fossa. Pre- and postsurgical neuropsychological assessments were completed within 4 months of resection [including WAIS-III: Block Design, Similarities, Digit Span, Digit Symbol; HVLT-R; Controlled Oral Word Association (COWA); Token Test; Trail Making Test (TMT)]. Scores at or below -1.5 SDs from normative means were considered impaired. Reliable change indices classified change in NCF performances as Declined or Stable/Improved. RESULTS: Demographic and tumor characteristics (histology/volume/extent of resection) did not differ by hemisphere. Presurgical NCF impairment was most frequent on COWA (25%), HVLT-R Total Recall (42%), Delayed Recall (41%), Recognition (24%), TMT-A (26%), and TMT-B (24%). In total, 50% of patients evidenced pre- to postoperative interval decline on at least 1 measure, which was most frequent on the HVLT-R Total Recall (26%) and TMT-B (23%). While not statistically significant, trends suggested older patients with greater extent of resection, and those with left frontal tumors were at greatest risk. CONCLUSIONS: NCF impairment was relatively common in patients with frontal lobe glioma in the pre-operative period in the domains of memory and executive functioning. Decline following frontal lobectomy was less common. Nonetheless, a sizeable proportion of patients experience some postoperative decline, most commonly in memory and executive functioning. Older patients with left frontal lesions may be at increased risk.
Phylogenetic and Genomic Analyses Resolve the Origin of Important Plant Genes Derived from Transposable Elements
Authors: Zoé Joly-Lopez, Douglas R. Hoen, Mathieu Blanchette, Thomas E. Bureau
Journal: Molecular Biology and Evolution (2016)

Once perceived as merely selfish, transposable elements (TEs) are now recognized as potent agents of adaptation. One way TEs contribute to evolution is through TE exaptation, a process whereby TEs, which persist by replicating in the genome, transform into novel host genes, which persist by conferring phenotypic benefits. Known exapted TEs (ETEs) contribute diverse and vital functions, and may facilitate punctuated equilibrium, yet little is known about this process. To better understand TE exaptation, we designed an approach to resolve the phylogenetic context and timing of exaptation events and subsequent patterns of ETE diversification. Starting with known ETEs, we search in diverse genomes for basal ETEs and closely related TEs, carefully curate the numerous candidate sequences, and infer detailed phylogenies. To distinguish TEs from ETEs, we also weigh several key genomic characteristics including repetitiveness, terminal repeats, pseudogenic features, and conserved domains. Applying this approach to the well-characterized plant ETEs MUG and FHY3, we show that each group is paraphyletic and we argue that this pattern demonstrates that each originated in not one but multiple exaptation events. These exaptations and subsequent ETE diversification occurred throughout angiosperm evolution including the crown group expansion, the angiosperm radiation, and the primitive evolution of angiosperms. In addition, we detect evidence of several putative novel ETE families. Our findings support the hypothesis that TE exaptation generates novel genes more frequently than is currently thought, often coinciding with key periods of evolution.
Paclitaxel poliglumex (PPX), cisplatin and concurrent radiation for esophageal and gastric cancer: A phase I study
Authors: T. Dipetrillo, D. Evans, P. Akerman, T. Miner, R. Millis, M. Jean, D. Henderson, F. Oldham, A. Eisenfeld, H. Safran
Journal: Journal of Clinical Oncology (2007)

15130 Background: PPX is a conjugate of paclitaxel to a polyglutamate polymer. Preclinically, PPX demonstrated a radiation enhancement factor (REF) &gt;7.0, versus 1.5–2.0 for paclitaxel. (Milas et al Int J Rad Onc 55:2003, Li et al. Clin Cancer Res 6:2000). The maximally tolerated dose (MTD) of PPX was determined previously to be 70 mg/m 2 /week with concurrent radiation. We initiated a phase I study of PPX, cisplatin, and concurrent radiation with patients with esophageal and gastric cancer. Methods: Patients with esophageal or gastric cancer receiving chemoradiation for locoregional control, adjuvant, or neoadjuvant treatment were eligible. All patients received radiation at a dose of 50.4 Gy delivered in 28 fractions (5 fractions per week for 5 1/2 weeks), and cisplatin (25 mg/m 2 ) on days 1, 8, 15, 22, 29, and 36. PPX was given as a 10 minute infusion in escalating dosages prior to each cisplatin dose. Dose limiting toxicities (DLTs) were defined as grade 4 hematologic toxicity, esophagitis, nausea/vomiting, or dehydration, or any other grade 3/4 non-hematologic toxicity. Patients were enrolled in successive cohorts of three. The MTD was defined as the dose level at which no more than 2 of 6 patients have DLTs. Results: Eleven patients have been entered over 2 dose levels of PPX: 50 mg/m 2 (six patients, dose level 1), and 60mg/m 2 (5 patients, dose level 2). Five patients had esophageal cancer and six had gastric cancer. All histologies were adenocarcinomas. One of six patients treated at dose level had a DLT (esophagitis). Three of five patients had DLTs at dose level 2, including esophagitis, nausea, vomiting, and dehydration. Conclusions: PPX is a novel radiation sensitizer for patients with esophageal and gastric cancer. The MTD for PPX is 50 mg/m 2 /week in combination with cisplatin 25mg/ m 2 /week for 6 weeks, and 50.4 Gy concurrent radiation for patients with esophagogastric cancer. A phase II study of PPX/cisplatin and radiation will be initiated. No significant financial relationships to disclose.
TCTAP A-158 Valve Repositioning and Outcomes in Lotus Transcatheter Aortic Valve Replacement: Large Single Centre Study
Authors: Hashrul Rashid, Sarah Zaman, Satish Ramkumar, Rob Gooley, Liam McCormick, Damon Jackson, Ian T. Meredith
Journal: Journal of the American College of Cardiology (2016)
Abstract ES4-3: Regimens in HER2+ disease
Authors: SA Hurvitz
Journal: Cancer Research (2016)

Abstract The discovery of the HER2 alteration and subsequent development of HER2-targeted therapy has substantially improved the natural history of HER2-positive metastatic breast cancer. In the past 17-years, four biologically targeted agents have been approved for the treatment of this disease subtype. These therapeutic advances have, in large part, been responsible for the significant improvement in median overall survival that can be expected now for a patient diagnosed with advanced HER2+ disease. While this progress has been remarkable, long-term durable remission is still rare, as the vast majority of patients will experience tumor progression with all available therapies. Thus the development of agents that prevent or circumvent mechanisms of resistance is still needed. During this educational session, data relating to the use of trastuzumab, lapatinib, pertuzumab and trastuzumab emtansine will be explored in detail. Regimens involving chemotherapy, anti-hormonal treatment, and combinations of HER2-targeted agents will be evaluated. Specifically, questions surrounding optimal choice for first- and second-line therapy will be addressed by discussing the results of the CLEOPATRA, EMILIA and MARIANNE trials. The challenge of treating central nervous system metastases will be examined with a focus on promising agents under clinical investigation. In addition, differences in treatment response and disease outcome will be explored based on hormone receptor co-expression or activation of the PI3K pathway. As key evidence is discussed, the audience will be led through the decision-making process using case-based examples. Finally, innovative treatments undergoing clinical evaluation will be considered with a critical appraisal of preclinical and early clinical data. It is expected that by the end of this session, audience members will possess an in-depth understanding of data relating to optimal treatment of HER2+ advanced disease and will be aware of promising avenues of research for continued areas of unmet need. Citation Format: Hurvitz SA. Regimens in HER2+ disease. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr ES4-3.
Colchicine in the Experimental Chemotherapy of Cancer
Authors: R. J. Ludford
Journal: JNCI Journal of the National Cancer Institute (1945)

Colchicine in the Experimental Chemotherapy of Cancer R. J. Ludford R. J. Ludford Laboratories of the Imperial Cancer Research Fund, Mill Hill, London Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 6, Issue 2, October 1945, Pages 89–101, https://doi.org/10.1093/jnci/6.2.89 Published: 01 October 1945
Acute Ipsilateral Renal Dysfunction after Partial Nephrectomy in Patients with a Contralateral Kidney: Spectrum Score to Unmask Ischemic Injury
Authors: Zhiling Zhang, Juping Zhao, Wen Dong, Diego Aguilar Palacios, Erick M. Remer, Jianbo Li, Sevag Demirjian, Joseph Zabell, Steven C. Campbell
Journal: European Urology (2016)
Wt Kras and gene expression levels of VEGFR2, EGFR, and ERCC-1 associated with progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line 5-FU or capecitabine with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV)
Authors: A. B. El-Khoueiry, A. Pohl, K. Danenberg, J. Cooc, W. Zhang, D. Yang, H. Singh, J. Shriki, S. Iqbal, H. J. Lenz
Journal: Journal of Clinical Oncology (2009)

4056 Background: While wild type (wt) Kras is associated with improved outcome to anti-EGFR therapy in pts with mCRC, there are no identified predictors of outcome for FOLFOX/BV. We evaluated Kras status and expression of genes involved in angiogenesis, DNA repair and 5-FU metabolism in 68 patients treated with FOLFOX/BV or XELOX/BV. These genes included VEGF, VEGF-receptor 2 (KDR), Cox-2, IL 6 and 8, chemokine-receptors 1 &amp; 2, EGFR and ERCC-1. Methods: Tissue samples from 68 patients with mCRC were analyzed. mRNA was extracted from laser-capture-microdissected tumor tissue. cDNA was prepared by reverse transcription and quantitation of the candidate genes was performed using a fluorescence- based real-time detection method (TaqMan). Allele specific RT-PCR was performed to determine Kras mutation status in codons 12 and 13. Results: There were 68 pts (38 males, 30 females), median age: 56 years (range 29–81). All received first line 5FU, oxaliplatin and BV (28 FOLFOX/BV, 40 XELOX/BV). Radiologic response: 1 CR, 39/68 (57%) PR, 27/68 (40%) SD, and 1 PD. Median OS is not reached. At a median follow-up of 32.0 months (mo) (range: 2.3–47.8 mo), the median PFS was 12.4 mo (95% CI: 9.8–15.2). Kras mutation was identified in 39 pts (57%). RR was 64% in pts with wt Kras and 52% in pts with mutant Kras (p=0.33). PFS was significantly longer for pts with wt kras compared to pts with mutant kras (13.7 mo [95% CI: 6.9–13.2] versus 8.3 mo [95%CI: 6.9–13.2], P=0.039). High EGFR (median PFS: 15.2 mo; 95% CI 11.7–16.5 mo), high VEGFR2 (median PFS: 13.9 mo; 95% CI 11.0–16.5 mo), and low ERCC1 (median PFS: 12.4 mo; 95% CI 10.9–16.4 mo) were associated with longer PFS compared to low EGFR (median PFS: 7.9 mo; 95% CI 6.9–11.0 mo, P=0.040), low VEGFR2 (median PFS: 7.2 mo; 95% CI 6.5–8.1 mo, P=0.032), and high ERCC1 (median PFS: 9.6 mo; 95% CI 5.8–15.2 mo, P=0.045). Conclusions: To our knowledge, this is the first report of a potential association between Kras status as well as gene expression levels of VEGFR2, ERCC-1 and EGFR and clinical outcome to FOLFOX/BV therapy in pts with mCRC. Prospective clinical trials are needed to validate these results. [Table: see text]
Clonal Diversity Analysis Of Integrating Vector Transduced Hematopoietic Cells Using LAM-PCR Followed By Illumina-Based Next-Generation Sequencing Is Affected By False Positivity That Arises From Both Reaction Biochemistry and Bioinformatic Analysis
Authors: Michael R. Greene, Michael Rusch, Chunlao Tang, Jinghui Zhang, Brian P. Sorrentino
Journal: Blood (2013)
THU0227 Postoperative Infection Rates After Surgery with Prosthesis in Patients with Ankylosing Spondylitis Treated by TNF-Alpha Blockade Compared to Conventional Nsaids
Authors: S.-J. Hong, S.-H. Lee, H.-R. Kim, H.W. Kim, H.-I. Yang
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Some patients with severely advanced ankylosing spondylitis (AS) need to replace or correct destructed joints by surgical treatment. Among these patients, some patients who don9t respond sufficiently to conventional NSAIDs have to be treated by anti-TNF alpha blockades. We reviewed these patients to assess postoperative infection rate after surgery with prosthesis. <h3>Methods</h3> We retrospectively reviewed the medical records of the patients with AS who experienced the surgery with prosthesis in Kyung Hee university hospital at Gangdong in Seoul, South Korea from Mar 2006 to May 2014. <h3>Results</h3> Total 307 patients underwent the surgeries such as total hip replacement (THR) or corrective osteotomy of spine. Among them, 25 patients have been treated by TNF alpha blockades after surgery. 9 patients had been treated by TNF alpha blockade before the surgery. Total follow-up period was 2.5±2.2 years per person. Their average ages for surgeries are 44.5±11.9 years. Among them, 13 patients had THR and the others had corrective osteotomy in spine. 11 patients have been treated by adalimumab, 9 patients have been treated by etanercept and 5 patients have been treated by infliximab. There was no wound complication associated with infection after the surgery during follow-up period in the group of patients treated by TNF alpha blockade. But in the group of patients who had been treated by conventional NSAIDs, one patient had wound infection after spine surgery. His age was 62 and he had uncontrolled DM. <h3>Conclusions</h3> There is no increased risk of infection after the surgeries using prosthesis in patients with AS treated by TNF alpha blockade compared to the patients treated by conventional NSAIDs. <h3>References</h3> Giles JT, Bartlett SJ, Gelber AC, Nanda S. Tumor Necrosis Factor Inhibitor Therapy and Risk of Serious Postoperative Orthopedic Infection in Rheumatoid Arthritis. Arthritis &amp; Rheumatism. 2006;55(2):333-7. Gilson M, Gossec L, Mariette X, Gherissi D. Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor a-blockers: a case-control study. Arthritis Research &amp; Therapy. 2010;12(4):145. Listing J, Strangfeld A, Kary S, Rau R. Infections in Patients With Rheumatoid Arthritis Treated With Biologic Agents. Arthritis &amp; Rheumatism. 2005;52(11):3403-12. <h3>Disclosure of Interest</h3> None declared
Mindfulness-Based Cognitive Therapy and the Prevention of Depressive Relapse
Authors: Richard J. Davidson
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Case 1-1999
Authors: Timothy K. Vartanian, Suzanne de la Monte
Journal: New England Journal of Medicine (1999)

Presentation of CaseA 53-year-old right-handed man was admitted to the hospital in December because of fever and an altered mental state.The patient had been well until two weeks earlier, when a cough and rhinorrhea developed. Three days before admission, he became lethargic, febrile, and forgetful. On the day before admission, he slept all evening and missed dinner. On the morning of admission, he was barely responsive. He was taken to another hospital, where a lumbar puncture was performed (Table 1). Ceftriaxone was administered, and he was transferred to this hospital.The patient worked in a sedentary occupation. He . . .
Responses to the combination of the glycolytic inhibitor 2-deoxy-glucose (2DG) and docetaxel (DC) in patients with lung and head and neck (H/N) carcinomas
Authors: L. E. Raez, V. Langmuir, K. Tolba, C. M. Rocha-Lima, K. Papadopoulos, S. Kroll, M. Brawer, J. Rosenblatt, A. Ricart, T. Lampidis
Journal: Journal of Clinical Oncology (2007)

14025 Background: We demonstrated in mouse xenografts that the combination of docetaxel chemotherapy with 2DG is feasible and increases responses against tumors (CancerRes; 2004 64:31–4). Methods: To determine the maximum tolerated dose (MTD) of daily oral doses of 2DG given alone and in combination with weekly docetaxel (DC) in patients (pts) with advanced malignancies who had relapsed after chemotherapy, and to evaluate the pharmacokinetics (PK) of 2DG alone and in combination with weekly DC. 2DG was initially administered orally once daily for 7 days every other week starting at a dose of 2 mg/kg, and DC was administered at 30mg/m2 for 3 of every 4 weeks. A modified accelerated titration design was used. Following completion of the every other week (EOW) 2DG dosing regimen, 3 weeks on and 1 week off (3–1W) dosing; and then continuous (CW) 2DG dosing were investigated. Results: 21 pts were enrolled in the EOW dosing at 2DG doses up to 88 mg/kg/day; another 10 pts were enrolled in the other dosing regimens. 5 pts had lung cancer (4 NSCLC + 1 SCLC); and another 6 pts had H/N cancers. One pt discontinued for DC-related sensory neuropathy. Single cases of DLT occurred - asymptomatic (64mg/kg) and symptomatic (88 mg/kg) Grade 3 hyperglycemia. The MTD was not reached with the EOW regimen. 2DG is rapidly absorbed (Tmax 0.5–1h) with a half-life of 5–10h. 2DG exhibits linear PK following single and multiple doses with minimal accumulation after multiple doses at 63 and 88 mg/kg. 2DG PK and DC PK do not alter each other. One of 18 evaluable pts in the EOW dosing with breast cancer had a partial response (PR). Another 8 pts achieved disease stabilization (SD) among them: 2 of 4 pts with NSCLC, 2 of 6 pts with H/N cancers, 1 pt with thyroid cancer, and 1 of 3 pts with adenoidcystic carcinoma. The others were unknown primary and a breast lymphoma. Also the MTD was not reached at 63mg/kg (3–1W) dosing where one patient with H/N cancer achieved stabilization of his disease. Enrollment of pts in the CW regimen is ongoing now. Conclusions: The combination of 2DG and DC appears to be feasible and safe with no evidence of PK interactions. Evidence of anti-tumor activity was observed in patients with NSCLC and H/N cancers. No significant financial relationships to disclose.
A Triple Rare E709K and L833V/H835L EGFR Mutation Responsive to an Irreversible Pan-HER Inhibitor: A Case Report of Lung Adenocarcinoma Treated with Afatinib
Authors: Stefano Frega, PierFranco Conte, Matteo Fassan, Valentina Polo, Giulia Pasello
Journal: Journal of Thoracic Oncology (2016)